Literature DB >> 11356962

Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

N H Gruener1, F Lechner, M C Jung, H Diepolder, T Gerlach, G Lauer, B Walker, J Sullivan, R Phillips, G R Pape, P Klenerman.   

Abstract

Hepatitis C virus (HCV) sets up persistent infection in the majority of those exposed. It is likely that, as with other persistent viral infections, the efficacy of T-lymphocyte responses influences long-term outcome. However, little is known about the functional capacity of HCV-specific T-lymphocyte responses induced after acute infection. We investigated this by using major histocompatibility complex class I-peptide tetrameric complexes (tetramers), which allow direct detection of specific CD8+ T lymphocytes ex vivo, independently of function. Here we show that, early after infection, virus-specific CD8+ T lymphocytes detected with a panel of four such tetramers are abnormal in terms of their synthesis of antiviral cytokines and lytic activity. Furthermore, this phenotype is commonly maintained long term, since large sustained populations of HCV-specific CD8+ T lymphocytes were identified, which consistently had very poor antiviral cytokine responses as measured in vitro. Overall, HCV-specific CD8+ T lymphocytes show reduced synthesis of tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) after stimulation with either mitogens or peptides, compared to responses to Epstein-Barr virus and/or cytomegalovirus. This behavior of antiviral CD8+ T lymphocytes induced after HCV infection may contribute to viral persistence through failure to effectively suppress viral replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356962      PMCID: PMC114267          DOI: 10.1128/JVI.75.12.5550-5558.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.

Authors:  G Missale; R Bertoni; V Lamonaca; A Valli; M Massari; C Mori; M G Rumi; M Houghton; F Fiaccadori; C Ferrari
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.

Authors:  D K Wong; D D Dudley; N H Afdhal; J Dienstag; C M Rice; L Wang; M Houghton; B D Walker; M J Koziel
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

3.  A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers.

Authors:  O Planz; S Ehl; E Furrer; E Horvath; M A Bründler; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

4.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.

Authors:  H M Diepolder; R Zachoval; R M Hoffmann; E A Wierenga; T Santantonio; M C Jung; D Eichenlaub; G R Pape
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

5.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

7.  Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif.

Authors:  A Cerny; J G McHutchison; C Pasquinelli; M E Brown; M A Brothers; B Grabscheid; P Fowler; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

8.  Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

Authors:  M F Callan; L Tan; N Annels; G S Ogg; J D Wilson; C A O'Callaghan; N Steven; A J McMichael; A B Rickinson
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

9.  Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes.

Authors:  A Gallimore; A Glithero; A Godkin; A C Tissot; A Plückthun; T Elliott; H Hengartner; R Zinkernagel
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

10.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

View more
  186 in total

Review 1.  T cell responses to viral infections: lessons from lymphocytic choriomeningitis virus.

Authors:  Aaruni Khanolkar; Michael J Fuller; Allan J Zajac
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load.

Authors:  Annetie Oxenius; Andrew K Sewell; Sara J Dawson; Huldrych F Günthard; Marek Fischer; Geraldine M Gillespie; Sarah L Rowland-Jones; Catherine Fagard; Bernard Hirschel; Rodney E Phillips; David A Price
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

3.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

Review 4.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver.

Authors:  Krystle A Lang Kuhs; Roberta Toporovski; Arielle A Ginsberg; Abby L Olsen; Devon J Shedlock; Matthew P Morrow; Jian Yan; Rebecca G Wells; David B Weiner
Journal:  Hum Vaccin       Date:  2011-12-01

6.  Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.

Authors:  Dennis J Hartigan-O'Connor; Din Lin; James C Ryan; Valentina A Shvachko; Myrna L Cozen; Mark R Segal; Norah A Terrault; Lewis L Lanier; M Michele Manos; Joseph M McCune
Journal:  J Infect Dis       Date:  2013-12-10       Impact factor: 5.226

7.  Dendritic cell co-stimulatory and co-inhibitory markers in chronic HCV: an Egyptian study.

Authors:  Hanan Fouad; Maissa Saeed El Raziky; Rasha Ahmed Abdel Aziz; Dina Sabry; Ghada Mahmoud Abdel Aziz; Manal Ewais; Ahmed Reda Sayed
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 8.  Treatment failure in hepatitis C: mechanisms of non-response.

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Hepatol       Date:  2008-12-03       Impact factor: 25.083

9.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.